NIAID DAIT CLINICAL PRODUCTS CENTER (CPC) for Studies of Radiation/Nuclear Countermeasures Research

NIAID DAIT 辐射/核对策研究临床产品中心 (CPC)

• 批准号: 10672843
• 负责人: ANBU DEVASAHAYAM
• 金额: $ 109.31万
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10672843
• 关键词: Biological Products; Clinical; Clinical Research; Clinical Trials; Contracts; Equipment and supply inventories; Funding; Investigation; National Institute of Allergy and Infectious Disease; Pharmacologic Substance; Placebos; Prevention; Product Labeling; Radiation; Research; Role; Schedule; Services; infectious disease treatment; nuclear countermeasure; programs; vaccine trial

The Clinical Product Center under contract, provides Investigational Product Services for all DAIT-funded and/or sponsored clinical research programs and other NIAID-funded clinical trials as needed. Studies to be supported include radiation/nuclear countermeasures research. Additionally, and on an as-needed basis, clinical trials of infectious disease treatment, prevention and other vaccine studies. Investigational Products to be studied include schedule I through VI pharmaceutical agents, biologics, and other agents.

合同下的临床产品中心为所有dait资助和/或赞助的临床研究计划以及其他NIAID资助的临床试验提供了研究产品服务。需要支持的研究包括辐射/核对策研究。另外，在需要的基础上，是传染病治疗，预防和其他疫苗研究的临床试验。要研究的研究产品包括通过VI制药剂，生物制剂和其他代理商的附表I。